Thursday, January 1, 2026 1/1/2026

Predicting risk of systemic autoimmune disease in patients with positive antinuclear antibodies

Award Number: R01AR080629
ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2022
PERIOD OF PERFORMANCE END DATE: 02/28/2027

Group Awards By:

View Award Description

Predicting risk of systemic autoimmune disease in patients with positive antinuclear antibodies - Project Summary Providers across multiple specialties face challenges in determining the clinical significance of a positive antinuclear antibody (ANA). While a positive ANA is highly sensitive for autoimmune disease, it is non-specific with up to 20% of the general population having a positive ANA without having autoimmune disease. Risk models to aide clinicians in stratifying positive ANA patients do not currently exist. By identifying high-risk patients, providers could properly triage patients for prompt treatment to reduce autoimmune disease-related morbidity and mortality. Our long-term goal is to build risk models in the electronic health record (EHR) for autoimmune diseases that improve outcomes. The overall objective of this proposal is to identify positive ANA patients who are at high risk for developing autoimmune disease to facilitate appropriate triage to rheumatology for earlier diagnosis and treatment. Our institution with expertise in biostatistics, biomedical informatics, and implementation science has demonstrated success in building and testing robust EHR risk models. Building upon this well-established infrastructure, we hypothesize that we can use available EHR data to identify positive ANA patients that are high risk for autoimmune disease. We hypothesize that using tailored risk assessments in real- time in the EHR can reduce time to autoimmune disease diagnosis and treatment. We will test these hypotheses with the following specific aims: (1) Refine and validate features available in the EHR to distinguish positive ANA patients who develop autoimmune disease from positive ANA patients who do not develop autoimmune disease and (2) Conduct an adaptive, randomized, pragmatic evaluation of an autoimmune disease risk model in the EHR to risk- stratify patients with a positive ANA. For Aim 1, we will validate a risk model for autoimmune disease in positive ANA patients using EHR data with logistic regression and machine learning methods. For Aim 2, we will deploy a risk model for autoimmune disease in real-time in the EHR. We will randomize positive ANA patients to either have a risk score from the model displayed and acted upon vs. not having a risk score displayed or usual care. We will assess if having this EHR system change with a risk score calculated and shared with the ordering provider compared to usual care affects time to autoimmune disease diagnosis and treatment. Our proposal is innovative in that it not only builds a predictive risk model for autoimmune disease but also deploys and assesses if the model impacts patient outcomes. For expected outcomes, we anticipate deploying an EHR risk model that identifies positive ANA patients at high risk for developing autoimmune disease and decreases time to diagnosis and treatment.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	4	11/20/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $401,415 )
2025	2025	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	4	2/19/2025	NON-COMPETING CONTINUATION	$372,447
2025	2025	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Arthritis, Musculoskeletal and Skin Diseases Research	001	4	5/15/2025	NON-COMPETING CONTINUATION	$28,968
														Subtotal = $401,415

Issue Date FY: 2024 ( Subtotal = $401,415 )
2024	2024	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	3	3/7/2024	NON-COMPETING CONTINUATION	$372,447
2024	2024	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Arthritis, Musculoskeletal and Skin Diseases Research	001	3	6/13/2024	NON-COMPETING CONTINUATION	$28,968
														Subtotal = $401,415

Issue Date FY: 2023 ( Subtotal = $422,004 )
2023	2023	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	2	3/17/2023	NON-COMPETING CONTINUATION	$422,004
														Subtotal = $422,004

Issue Date FY: 2022 ( Subtotal = $400,690 )
2022	2022	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	1	4/6/2022	NEW	$400,690
														Subtotal = $400,690

Grand Total All Awards = $1,625,524

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Predicting risk of systemic autoimmune disease in patients with positive antinuclear antibodies

Award Number: R01AR080629

ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2022

PERIOD OF PERFORMANCE END DATE: 02/28/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer